Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1493 • ACR Convergence 2020
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
Stephanie Shoop-Worrall¹, Kimme Hyrich², Lucy Wedderburn³, Wendy Thomson⁴ and Nophar Geifman⁵, ¹Centre for Health Informatics, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³UCL, UCLH, GOS Institute of Child Health, London, United Kingdom, ⁴Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Health Informatics, The University of Manchester, Manchester
Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…
Abstract Number: 0469 • ACR Convergence 2020
IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome
Denny Gao¹, Maggie Henderlight¹, Christopher Woods¹, Alexei Grom¹, Sherry Thornton¹, Michael Jordan¹, Katheryn Wikenheiser-Brokamp¹ and Grant Schulert², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…
Abstract Number: 0727 • ACR Convergence 2020
Hip Involvement Leads to Poor Outcome in Adulthood in Children with Enthesitis Related Arthritis (ERA) Category of Juvenile Idiopathic Arthritis (JIA)
Naveen R¹, Namita Mohindra¹, Neeraj Jain¹ and Amita Aggarwal², ¹Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is the commonest category of JIA seen in India and constitutes 30-40% of all JIA patients. There are many studies…
Abstract Number: 1494 • ACR Convergence 2020
Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts
Alessandra Alongi¹, Maria Trachana², Valda Stanevicha³, Laura Marinela Ailioaie⁴, Elena Tsitsami⁵, Angelo Ravelli⁶, Alessandro Consolaro⁶ and Nicolino Ruperto⁷, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²Aristotle University of Thessaloniki, Thessaloníki, Greece, ³Riga Stradins University, Riga, Latvia, ⁴Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ⁵Aghia Sophia Childrens Hospital, Athens, Greece, ⁶Università degli Studi di Genova, Genoa, Italy, ⁷Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
Abstract Number: 0470 • ACR Convergence 2020
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Amelie Jule¹, Kacie Hoyt¹, Kevin Wei², Siobhan Case³, Margaret Chang¹, Ezra Cohen¹, Fatma Dedeoglu¹, Melissa Hazen¹, Jonathan Hausmann⁴, Olha Halyabar⁵, Erin Janssen⁵, Pui Lee⁶, Jeffrey Lo¹, Mindy Lo¹, Esra Meidan⁷, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel⁵, Talal Chatila¹, Peter Nigrovic⁸ and Lauren Henderson⁹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵Children's Hospital/Boston Medical Center, Boston, MA, ⁶1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁷Boston Children's Hospital, Somerville, MA, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁹Boston Children's Hospital, Watertown, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…
Abstract Number: 0728 • ACR Convergence 2020
Clinical Outcomes of Juvenile Arthritis in Adulthood: A Systematic Review
Lily Siok Hoon Lim¹, Woo Jin Kim², Yushi Wang² and Kaien Gu³, ¹University of Manitoba, Children's Hospital of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba Max Rady College of Medicine, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Juvenile arthritis (JA) is the most common pediatric rheumatic disease, with potentially permanent functional impacts on patients long after initial diagnosis. Little is known…
Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Hermine I Brunner¹, Jonathan Akikusa², Eslam Al-Abadi², John Bohnsack³, Alina Lucica Boteanu², Gaelle Chedeville⁴, Ruben Cuttica², Wendy De La Pena⁴, Lawrence Jung⁴, Ozgur Kasapcopur², Katarzyna Kobusinska², Grant Schulert¹, Claudia Neiva², Rafael Rivas-Chacon⁴, Juan Cruz Rizo Rodriguez², Monica Vazquez-Del Mercado², Linda Wagner-Weiner⁴, Jennifer E Weiss¹, Carine Wouters², Ricardo M Suehiro⁵, Holly Posner⁶, Ann Wouters⁶, Keith S Kanik⁷, Zhen Luo⁸, Alberto Martini², Daniel J Lovell¹ and Nicolino Ruperto², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China (People's Republic)
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…
Abstract Number: 0710 • ACR Convergence 2020
Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?
Alina Lucica Boteanu¹, Andrea Briones-Figueroa², Laura Calvo-Sanz², África Andreu Suárez² and Antía García-Fernández², ¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: Data about when is the best moment to start BT in Juvenile Idiopathic Arthritis (JIA) patients and the impact of this prompt initiation are…
Abstract Number: 0729 • ACR Convergence 2020
Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up
Francesca Minoia¹, Luca Marelli², Gisella Beatrice Beretta³, Micol Romano⁴, Elisabetta Miserocchi⁴, Chiara Mapelli³, Antonella Petaccia³, Stefano Lanni³, Irene Pontikaki⁴, Giovanni Filocamo³ and Rolando Cimaz⁵, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ²San Giuseppe Hospital, IRCCS Multimedica, Milan, Italy, Milan, Italy, ³Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ⁴ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, ⁵ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy
Background/Purpose: Uveitis is the most common extra-articular complication of juvenile Idiopathic arthritis (JIA). Due to its typical indolent and chronic course, children with this condition…
Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 0711 • ACR Convergence 2020
Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Colleen Correll¹, Peter Shrader², Anne Dennos³, Thomas Phillips², Natalie Shiff⁴, Ruud Verstegen⁵ and Timothy Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Florida, Gainesville, FL, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
Abstract Number: 1617 • ACR Convergence 2020
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Esi Morgan², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Nancy Griffin⁶, Kerry Ferraro⁷, Stephanie Loos⁶, Tingting Qiu⁸, Anne Paul⁹, Jon Burnham¹⁰, Michelle Batthish¹¹, Beth Gottlieb¹², Danielle Bullock¹³, Melissa Hazen¹⁴, Ronald Laxer¹⁵, Tzielan Lee¹⁶, Melissa Mannion¹⁷, Judyann Olson¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Charles Spencer²¹, Jennifer E Weiss²² and C. April Bingham²³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Nationwide Children's Hospital, Houston, TX, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, ¹⁰Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹McMaster Children's Hospital, Hamilton, ON, Canada, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Boston Children's Hospital, Boston, MA, ¹⁵The Hospital for Sick Children, Toronto, ON, Canada, ¹⁶Stanford University School of Medicine, Palo Alto, CA, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Medical College of Wisconsin, Milwaukee, WI, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Mississippi, Jackson, MS, ²²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²³Penn State Children's Hospital, Allentown, PA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient…
Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
Abstract Number: 0731 • ACR Convergence 2020
Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
Jackeline Rodriguez-Smith¹, Virginia Miraldi Utz², Amy Cassedy¹, Sherry Thornton¹, Grant Schulert³, Alyssa Sproles⁴, Najima Mwase¹, Theresa Hennard¹, Mekibib Altaye², Alexei Grom¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati
Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].